Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

1.2K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.2K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

235
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
235
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Transcription Factors02:16

Transcription Factors

82.9K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.9K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Group Therapy01:26

Group Therapy

469
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between particulate air pollution and venous thromboembolism: A systematic literature review.

European journal of internal medicine·2015
Same author

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

Seminars in thrombosis and hemostasis·2015
Same author

Correlation between ABO Blood Group, and Conventional Hematological and Metabolic Parameters in Blood Donors.

Seminars in thrombosis and hemostasis·2015
Same author

Alcohol consumption and venous thromboembolism: friend or foe?

Internal and emergency medicine·2015
Same author

Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature.

Seminars in thrombosis and hemostasis·2015
Same author

Management of Bleeding Associated with New Oral Anticoagulants.

Seminars in thrombosis and hemostasis·2015

Related Experiment Video

Updated: Feb 13, 2026

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation
10:11

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

11.9K

Non-factor replacement therapy for haemophilia: a current update.

Massimo Franchini1, Pier Mannuccio Mannucci2

  • 1Department of Transfusion Medicine and Haematology, "Carlo Poma" Hospital, Mantua, Italy.

Blood Transfusion = Trasfusione Del Sangue
|March 9, 2018
PubMed
Summary

Developing alloantibodies against factor VIII (FVIII) or factor IX (FIX) complicates hemophilia treatment. This review explores innovative therapies like emicizumab, fitusiran, and concizumab for patients with inhibitors.

More Related Videos

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.6K
Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients
11:26

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Published on: July 14, 2018

18.0K

Related Experiment Videos

Last Updated: Feb 13, 2026

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation
10:11

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

11.9K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.6K
Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients
11:26

Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients

Published on: July 14, 2018

18.0K

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Background:

  • Alloantibody development against factor VIII (FVIII) or factor IX (FIX) is a major challenge in hemophilia treatment.
  • These inhibitors render standard factor replacement therapy ineffective, increasing patient morbidity and mortality risks.
  • Existing treatments include bypassing agents like activated prothrombin complex concentrate and recombinant activated factor VII.

Purpose of the Study:

  • To review innovative therapeutic agents for hemophilia patients with inhibitors.
  • To provide an update on the clinical development of novel coagulation-enhancing and anticoagulant pathway-inhibiting agents.

Main Methods:

  • Literature review of recent clinical trials and research publications.
  • Focus on agents like emicizumab, fitusiran, and concizumab.
  • Analysis of mechanisms of action and current developmental stages.

Main Results:

  • Emerging therapies target coagulation enhancement (e.g., emicizumab) or inhibition of anticoagulant pathways (e.g., fitusiran, concizumab).
  • These novel agents represent a growing interest in managing hemophilia patients with inhibitors.
  • The review synthesizes current data on their clinical progress.

Conclusions:

  • Innovative therapies show promise in addressing the challenge of FVIII/FIX inhibitors in hemophilia.
  • Further clinical development is crucial for these agents to improve patient outcomes.
  • The landscape of hemophilia treatment is evolving with these new therapeutic options.